PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

Oncogene

Volumn 30, Issue 29, 2011, Pages 3222-3233

  Weigelt, B ^a   Warne, P H ^a   Downward, J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

breast cancer; everolimus; mTOR; PIK3CA; PP242; PTEN

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PP 242; SELUMETINIB; STAUROSPORINE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVE SITE; GENE ACTIVATION; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

MAMMALIA;

EID: 79960732694     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.42     Document Type: Article

References (63)

1. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F et al. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Res 67: 11565-11575.
2. American Type Culture Collection Standards Development Organization Workgroup ASN-000 (2010). Cell line misidentification: the beginning of the end. Nat Rev Cancer 10: 441-448.
3. Atkins MB, Yasothan U, Kirkpatrick P. (2009). Everolimus. Nat Rev Drug Discov 8: 535-536.
4. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775. (Pubitemid 41351083)
5. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H et al. (2009). Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106: 22299-22304.
6. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS et al. (1994). A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758.
7. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
8. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C et al. (2005). Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23: 5314-5322. (Pubitemid 46206985)
9. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF et al. (2003). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117-124. (Pubitemid 37433402)
10. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM et al. (2009). PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69: 3955-3962.
11. Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M et al. (2010). Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res 70: 4982-4994.
12. Dancey J. (2010). mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219.
13. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G et al. (2006). Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66: 5549-5554. (Pubitemid 43927103)
14. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T et al. (2010). Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.
15. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
16. Efeyan A, Sabatini DM. (2010). mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176.
17. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S et al. (2009). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27: 4536-4541.
18. Engelman JA. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
19. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619. (Pubitemid 44100518)
20. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632. (Pubitemid 28334795)
21. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. (2009). Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
22. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J et al. (2008). The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Suppl 57: 10.11.1-10.11.26.
23. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135. (Pubitemid 34155123)
24. Guertin DA, Sabatini DM. (2007). Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. (Pubitemid 47001784)
25. Gymnopoulos M, Elsliger MA, Vogt PK. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104: 5569-5574. (Pubitemid 47175721)
26. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
27. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. (2007). Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5: 195-201. (Pubitemid 46424000)
28. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD et al. (2009). Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7: 511-522.
29. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH et al. (2009). The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates glioma-genesis in vivo. Genes Dev 23: 1327-1337.
30. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. (2010). Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213.
31. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS et al. (2011). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther (e-pub ahead of print; doi:10.1158/1535-7163. MCT-10-0994).
32. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK et al. (2009). PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059.
33. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS et al. (2010). FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15: 428-435.
34. Lee GY, Kenny PA, Lee EH, Bissell MJ. (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365. (Pubitemid 46766981)
35. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI et al. (2005). Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11: 2875-2878. (Pubitemid 40525186)
36. Liu P, Cheng H, Roberts TM, Zhao JJ. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644.
37. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D et al. (2010). PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107: 10208-10213.
38. Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M et al. (2005). Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 18: 719-727. (Pubitemid 40676385)
39. Pampaloni F, Reynaud EG, Stelzer EH. (2007). The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845. (Pubitemid 47462131)
40. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE et al. (2007). PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13: 3577-3584. (Pubitemid 46955118)
41. Pickl M, Ries CH. (2009). Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28: 461-468.
42. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. (2010). A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465: 1033-1038.
43. Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ et al. (2010). The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 29: 1543-1552.
44. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559. (Pubitemid 40490050)
45. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43. (Pubitemid 24228298)
46. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
47. Serebriiskii I, Castello-Cros R, Lamb A, Golemis EA, Cukierman E. (2008). Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol 27: 573-585.
48. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
49. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al. (2008). Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3: e3065.
50. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
51. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V et al. (1998). Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 58: 3237-3242. (Pubitemid 28371058)
52. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W et al. (2008). A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 415: 97-110.
53. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R et al. (2010). Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013-2023.
54. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32.
55. Wang X, Jiang X. (2008). Post-translational regulation of PTEN. Oncogene 27: 5454-5463.
56. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F et al. (2002). beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205-216. (Pubitemid 41043976)
57. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R et al. (2008). PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105: 13057-13062.
58. Weigelt B, Bissell MJ. (2008). Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 18: 311-321.
59. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. (2010). HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D micro-environment. Breast Cancer Res Treat 122: 35-43.
60. Yamada KM, Cukierman E. (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610. (Pubitemid 47268064)
61. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al. (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13: 1576-1583. (Pubitemid 46450450)
62. Yuan TL, Cantley LC. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
63. Zhang S, Yu D. (2010). PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-4330.